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Hotspotmutations in splicing factor genes have been
recently reported at high frequency in hematological
malignancies, suggesting the importance of RNA
splicing in cancer. We analyzed whole-exome
sequencing data across 33 tumor types in The
Cancer Genome Atlas (TCGA), and we identified
119 splicing factor genes with significant non-silent
mutation patterns, including mutation over-repre-
sentation, recurrent loss of function (tumor suppres-
sor-like), or hotspot mutation profile (oncogene-like).
Furthermore, RNA sequencing analysis revealed
altered splicing events associated with selected
splicing factor mutations. In addition, we were able
to identify common gene pathway profiles associ-
ated with the presence of these mutations. Our
analysis suggests that somatic alteration of genes
involved in the RNA-splicing process is common
in cancer and may represent an underappreciated
hallmark of tumorigenesis.INTRODUCTION
Alternative pre-mRNA splicing is a major source of transcript di-
versity in mammalian cells and is orchestrated by a megadalton
complex called the spliceosome (Papasaikas and Valca´rcel,
2016). The major U2-type spliceosome constitutes five small nu-
clear ribonucleoprotein (snRNP) complexes (U1, U2, U4, U5, and
U6) and >150 proteins, while the minor U12-type spliceosome
contains five snRNPs and an unknown number of proteins,
many of which have analogous genes in the U2 spliceosome.
In a dynamic process, pre-mRNA non-coding intron sequences
are removed at specific splice sites, leaving coding exons that
are ligated to form mature mRNA. These introns and exons
contain sequences that are recognized by the core splicing ma-
chinery and are essential for recruitment and activation of the
splicing process. Additionally, there are cis silencer and
enhancer sequences that are recognized by accessory factors,
e.g., heterogeneous nuclear ribonucleoproteins (hnRNPs) and
serine/arginine-rich (SR) proteins, and these factors are respon-282 Cell Reports 23, 282–296, April 3, 2018 ª 2018 The Authors.
This is an open access article under the CC BY-NC-ND license (http://sible for splicing regulation (Wang et al., 2008). Recurrent so-
matic mutations of the splicing factor genes SF3B1, SRSF2,
U2AF1, and ZRSR2 were first discovered through whole-exome
sequencing in myelodysplastic syndrome (MDS) (Yoshida et al.,
2011), and they were later reported in other hematological malig-
nancies as well as solid tumors (Makishima et al., 2012; Papaem-
manuil et al., 2013; Haferlach et al., 2014; Lindsley et al., 2015;
Jeromin et al., 2014; Landau et al., 2015; Patnaik et al., 2013).
Differential splicing analysis using RNA sequencing data from
patient samples and pre-clinical models revealed that these so-
matic mutations induced transcriptome-wide splicing alterations
(Ferreira et al., 2014; DeBoever et al., 2015; Darman et al., 2015;
Zhang et al., 2015; Kim et al., 2015; Okeyo-Owuor et al., 2015;
Przychodzen et al., 2013; Madan et al., 2015).
The confluence of both DNA and RNA sequencing in TCGA
provide a unique opportunity to interrogate splicing deregulation
due to somatic mutation across human cancers. Although sys-
tematic analyses of mutations, copy number, and gene expres-
sion patterns of RNA-binding proteins (RBPs) have recently been
reported (Sebestye´n et al., 2016; Neelamraju et al., 2018), here
we focus on somatic mutations in known splicing factors and
alternative splicing events associated with selected mutations
across 33 tumor types and more than 10,000 samples. Further-
more, we compare how thesemutations affect gene pathways in
the affected lineages, and we examine their potential impact on
tumorigenesis.RESULTS
119 Splicing Factor Genes Carry Recurrent Mutations in
Hematological Cancers and Solid Tumors
We compiled and curated a catalog of 404 splicing factor genes
(Table S1; STAR Methods), and we prioritized genes with likely
driver mutations using two complementary approaches (Fig-
ure 1A). The first approach, MutSigCV (Lawrence et al., 2013),
ranks genes by statistical significance of somatic mutation per
cohort adjusted by mutation background of tumor type, gene
size, replication time, and gene expression levels. We identified
68 genes as significantly mutated in at least one cohort
(q value% 0.1). The second approach, a ratiometric method (Vo-
gelstein et al., 2013), identifies likely oncogenes and tumor sup-
pressors based on the observation that oncogenes are recur-
rently mutated at the same amino acid position (hotspot, HS),creativecommons.org/licenses/by-nc-nd/4.0/).
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whereas tumor suppressor genes are mutated through loss-of-
function (LoF) mutations throughout their length. Using this
method, we identified 77 genes as either likely oncogene (OG)
or tumor suppressor gene (TSG) using either individual tumor co-
horts (72 genes) or a pancan cohort of all samples (5 genes).
Similar results were also obtained by a recently published ratio-
metric method, 20/20+ (Tokheim et al., 2016) (Figure S1C).
Among the 77 genes, 27 were also identified by MutSigCV, while
50 were uniquely identified by this approach only. Finally, ZRSR2
was added as it has been previously identified in hematological
tumors as significantly mutated, though it did not meet our driver
gene criteria in TCGA. Together, we prioritized 119 genes as
likely harboring driver mutations (Table S1).
We mapped these 119 genes to known U2 and U12 spliceo-
some complexes and their associated proteins (Figure 1B;
Table S1A). Among components of the U2 spliceosome, we
observed that driver mutations primarily impacted proteins
involved in the early stages of splicing catalysis, frompre-catalytic
(complex A) to the first catalytic step (complex C). Proteins asso-
ciated with the U2 snRNP were especially well-represented
among hotspot mutants, including SF3B1, U2AF1, and PHF5A.
In the U12-type spliceosome, prior reports have described
ZRSR2 LoFmutations, primarily inMDS and secondary leukemia,
that are associated with the retention of U12 spliceosome introns
(Yoshida et al., 2011; Papaemmanuil et al., 2013; Haferlach et al.,
2014; Lindsley et al., 2015;Madan et al., 2015). Here we identified
3 recurrently mutated genes (SNRNP35, SNRNP48, and ZCRB1)
that are also part of the U12 spliceosome. The recurrent hotspot
mutations in SNRNP48 and ZCRB1 in acute myeloid leukemia
(LAML) indicate that U12-splicing deregulation in hematological
malignancies are more prevalent than previously reported.
Globally, the non-silent mutation rate of individual splicing fac-
tor genes is low, ranging from 0.16% (PHF5A) to 3.7% (SPEN)
(Figure S1A; Table S1B); however, we observed a number of
genes with exceptionally high mutation rates in otherwise infre-
quently mutated tumors (e.g., SF3B1 in uveal melanoma [UVM]
and FUBP1 in low-grade glioma [LGG]) (Figure S1A). Segre-
gating LoF and hotspot mutation rates in each gene by tumor
type revealed genes with high percentage of HS or LoF muta-
tions across multiple tumor types (Figure 1D), and we found
that LoF mutations are much more common than hotspot muta-
tions (Figure 1C). Overall, we observed a significant linear rela-
tionship between the number of samples with likely splicing fac-
tor driver mutations and the log10 mutation rate per sample in the
corresponding cohort (p = 4.02e11) (Figure S1B). Bladder car-
cinoma (BLCA), skin cutaneous melanoma (SKCM), and lung
adenocarcinoma (LUAD) were most likely to harbor non-silentFigure 1. 119 Splicing Factor Genes Are Mutated across All Tumor Co
(A) Prioritization of splicing factor genes with likely driver mutations.
(B) Hotspot (HS)- (red) and loss-of-function (LoF)- (blue) mutated genes in the p
mutation frequency (Table S1) is listed next to each gene.
(C) Genes are plotted as %hotspot or %LoF mutations for non-silent mutations a
colored blue.
(D) Heatmap view of %hotspot (bottom orange panel) or %LoF mutations (top blu
hotspot mutation high to low and%LoFmutation low to high from left to right. Tum
For comparison, the fraction of samples with non-silent mutations in any of the 11
non-silent mutation in each likely driver gene is given in the top bar chart.
See also Figure S1 and Table S1.
284 Cell Reports 23, 282–296, April 3, 2018mutations in any putative driver splicing factor, at more than
60% of patients in each cohort. Of these tumor types, BLCA
and UVM had significantly higher rates of splicing factor driver
mutations than would be expected by chance (p = 0.01 and
0.03, respectively), suggesting that splicing deregulation is an
important hallmark for these tumors.
Due to the importance of splicing factor mutations in cancer,
we analyzed the transcriptomic consequences associated with
mutations with exceptional frequency in a single cohort and
with hotspot (SF3B1, U2AF1, and SRSF2) or LoF mutations
(RBM10 and FUBP1) in samples that were not associated with
hyper-mutator phenotypes (see the STAR Methods).
SF3B1 Hotspot Mutations Induce Aberrant Splicing
SF3B1 has been reported to be the most frequently mutated
splicing factor gene in hematological malignancies and some
solid tumors, such as adenoid cystic carcinoma (Martelotto
et al., 2015), breast cancer (Cancer Genome Atlas Network,
2012), pancreatic cancer (Biankin et al., 2012), and melanomas
(Martin et al., 2013; Cancer Genome Atlas Network, 2015; Hintz-
sche et al., 2017). It is a member of the U2 complex and, along
with SF3B3 and PHF5A, binds to the branch point nucleotide in
the pre-catalytic spliceosome (Yan et al., 2016). Here, in a global
survey of SF3B1 mutations pan-cancer, we found somatic hot-
spot mutations that appear to cluster in the C-terminal HEAT
repeatdomains (HDs)4–12 (Figures2Aand2B;TableS2).Wepre-
viously reported that hotspot mutations in HDs 4–8 display aber-
rant splicing events enriched with alternative 30 splice sites (ss),
likely as a result of reduced branchpoint fidelity (Darman et al.,
2015). Here we also uncovered hotspot mutations in HDs 9–12,
including p.L833 (HD 9) in LAML, p.E902 (HD 11) in BLCA, and
p.R957 (HD 12) in endometrial cancer (UCEC) samples. These
hotspots appeared to be present mainly in these 3 tumor types,
resembling previous observations of SF3B1mutations in position
p.R625, which are primarily observed in melanomas.
We observed that overall the occurrence of hotspot mutations
in SF3B1 follows a specific periodicity of 40 amino acids, sug-
gesting a functional role for residues at these positions. Interest-
ingly, the majority of these positions are located at the edge of
the HEAT repeat helices of the SF3B1 protein structure (Fig-
ure 2B) (Yan et al., 2016; Cretu et al., 2016), suggesting they
are important for interactions with RNA or protein or for the
conformational flexibility of this super-helical domain. Previously
discovered hotspot mutations cluster in HDs 4–8 and near the
pre-mRNA-binding region, however, the hotspot mutations in
HDs 9–12 are located away from this region, raising the possibil-
ity they might induce unique splicing abnormalities.horts
ancan cohort are mapped to spliceosome complexes. The percent non-silent
cross TCGA (pancan). OG-like genes are colored red and TSG-like genes are
e panel) of all non-silent mutations per gene in each tumor cohort, sorted by%
or cohorts are sorted by averagemutation counts per sample (right green bar).
9 genes are shown as purple bars on the right. The number of samples with any
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See also Figure S2 and Tables S2 and S3.
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To test this hypothesis, we used the z-normalized percent
spliced-in (PSI) of published alternative 30 ss associated with
SF3B1 hotspot mutations in HDs 4–8 (Darman et al., 2015) to
stratify all TCGA solid tumor patient samples using principal-
component analysis (PCA) (Figures 2C and S2A). We found
that samples with previously identified hotspot mutations in
HDs 4–8 were separated from SF3B1 wild-type (WT) samples,
as expected. Interestingly, samples with non-hotspot mutations
in SF3B1 or mutations in hotspots in HDs 9–12 including those
with mutations at position p.E902, were mostly clustered with
WT samples, indicating these mutations do not confer the
same altered splicing phenotype. We then performed differential
splicing analysis using RNA sequencing data directly comparing
samples in BLCA with SF3B1 p.E902K (n = 6) to tumors of the
same lineage, which were WT with respect to all splicing factor
genes (n = 40), resulting in 134 significantly altered junctions (Fig-
ure 2D; Table S3). Though splicing alterations as a result of
p.E902K also favored alternative 30 ss, the selected 30 ss were
preferentially located downstream of the 30 ss used in the WT,
while 30 ss promoted by previously observed hotspots were
mostly found upstream (Figure 2E). Similar to 30 ss promoted
by previously identified hotspot mutations, alternative 30 ss and
exon inclusion junctions promoted by SF3B1 p.E902K were
also able to stratify solid tumor samples distinctly from samples
with other SF3B1mutations (Figure S2B). The p.R957Qmutation
was found to be co-occurring with POLE mutations in UCEC
and, thus, in samples with very high mutation rates, reducing
the likelihood that this specific SF3B1 mutation is functionally
relevant. Other hotspots, such as p.L833, did not have enough
samples to allow further functional validation of potential splicing
alterations.
U2AF1 and SRSF2 Hotspot Mutations Confer Altered
Splicing Based on Sequence Features
Hotspot mutations ofU2AF1 have been reported to alter exon in-
clusion ratios in both leukemia and lung adenocarcinoma (Przy-
chodzen et al., 2013; Brooks et al., 2014). U2AF1, like SF3B1, is
associated with the U2 complex, and it is known to recognize the
30 dinucleotide AG; and, along with its partner U2AF2 that binds
to the 30 poly-Y tract, it promotes assembly of the pre-catalytic
spliceosome (Wu et al., 1999). Hotspot mutations at amino
acid positions p.S34 and p.Q157 are common in hematological
malignancies (Papaemmanuil et al., 2013; Lindsley et al., 2015)
and confer distinct splicing phenotypes (Ilagan et al., 2015),
affecting exon inclusion rates based on the nucleotide in the
1 and +1 position relative to the 30 AG dinucleotide, respec-
tively. In TCGA, p.S34F/Y is the dominant hotspot mutationFigure 3. U2AF1 and SRSF2 Mutations in the Pancan Cohort and Diffe
(A) U2AF1 somatic mutations mapped to amino acid positions and annotated do
(B) Differential splicing events associated with U2AF1 p.S34F/Y hotspot mutatio
count, the PSI log2 fold change of each individual event is detailed in a boxplot.
(C) Consensus sequence motifs for exons preferentially used by mutant U2AF1
(D)SRSF2 somaticmutationsmapped to amino acid positions and annotated dom
mutant sample colored by tumor cohort.
(E) Differential splicing events associated with SRSF2 in-frame deletions in UVM
(F) Tetramer (CCNG and GGNG) enrichment analysis comparing cassette exons p
average tetramer occurrence frequency for all exons in that class. Fold change s
See also Tables S2 and S3.and is observed in multiple tumor types, most notably LAML,
LUAD, and UCEC (Figure 3A; Table S2). In contrast, U2AF1 mu-
tations at p.Q157 are rare and occur in only two samples.
To explore the functional impact of the U2AF1 p.S34 hotspot
mutations, we focused on LUAD and LAML, comparing mutant
samples (n = 15 LUAD and n = 6 LAML) to samples with no
known splicing factor gene mutation (n = 87 LUAD and n = 127
LAML). We observed an altered splicing phenotype dominated
by alternative 30 ss and cassette exon events, similar to results
obtained by Brooks et al. (2014) (Figure 3B; Table S3). Both
exon inclusion and exon skipping events were associated with
reduced usage of the 30 ss trinucleotide TAG, reflecting mutant
preference for either C or A in the 1 position. Interestingly, we
also observed the same motif selection for alternative 30 splicing
events, which had not been previously reported (Figure 3C).
SRSF2 is an auxiliary splicing factor that has been shown to
bind exonic pre-mRNA at specific motifs, where it acts as a
splicing enhancer. Both hotspot mutations and in-frame dele-
tions around position p.P95 have been reported, which increase
mutant SRSF2 affinity to the nucleotide sequence CCNG relative
to the sequence GGNG, resulting in altered exon inclusion
rates (Zhang et al., 2015; Kim et al., 2015). We found the majority
of SRSF2 somatic mutations in LAML (n = 20) (Figure 3D;
Table S2). Interestingly, we identified in-frame deletions in
UVM (n = 3), uncovering SRSF2 mutations in this disease. We
confirmed that deletions around p.P95 (n = 2) also induced
altered exon inclusion and exclusion as compared to WT sam-
ples (n = 20) (Figure 3E; Table S3), and we observed that
exons with increased inclusion rates displayed an enrichment
in CCNG versus GGNG sequence ratios (Figure 3F), consistent
with published results in hematological tumors.
RBM10 LoF Mutation Is Associated with Exon Inclusion
and a Corresponding Loss of Intron Retention Events in
LUAD and BLCA
RBM10 is an RNA-binding protein associated exclusively with
splicing repression (Wang et al., 2013), typically acting by bind-
ing in the intronic regions both up- and downstream of cassette
exons. It is most frequently mutated in LUAD (Cancer Genome
Atlas Research Network, 2014) and BLCA (Table S2), and the
mutations are mutually exclusive with other splicing factor
gene mutations (Figure 4A). RBM10 is located on the X chromo-
some, and its LoF mutations are the cause of the X-linked reces-
sive disorder TARP syndrome, affecting mainly males (Johnston
et al., 2010). We observed that RBM10 LoF mutations in LUAD
were also associated with the male gender (p = 0.002, Fisher’s
exact test), though this trend was not observed in BLCA, arential Splicing Associated with Hotspot Mutations
mains. Each dot represents a single mutant sample colored by tumor cohort.
ns in LUAD and LAML (corrected q-value < 0.05). Below each splicing event
versus WT U2AF1 across various alternative splicing events.
ains. Each bar (in-frame deletion) and dot (other mutations) represents a single-
.
referentially included or excluded by SRSF2mutant samples. Each value is the
ignificance was assessed using Student’s t test.
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disease that is found primarily inmales. In both diseases,RBM10
LoFmutations resulted in reduced mRNA expression (Figure 4B;
p value < 0.0001 in all comparisons, Student’s t test). Differential
splicing analyses comparing RBM10 LoF mutant tumors (n = 32)
and samples WT for all splicing factor genes (n = 87) identified
exon inclusion as the primary alternative splicing event in both
LUAD and BLCA (Figure 4C; Figure S3A; Tables S2 and S3).
This is consistent with earlier reports correlating the overexpres-
sion of RBM10 in HEK293 cells with exon skipping (Wang et al.,
2013).
We observed a significant overlap in exons included following
RBM10 loss in LUAD and exons previously reported to be both
excluded upon RBM10 overexpression and included following
knockdown (Figure S3B). Interestingly, RBM10 expression has
also been shown to correlate with retention of the introns flanking
the exons that are skipped due to its activity (Wang et al., 2013;
Figure S3C), and we observed the corresponding normal
splicing of these introns upon RBM10 loss in LUAD (Figure 4D).
The majority of genes with this pattern of altered splicing by
RBM10 LoF mutation were upregulated compared to RBM10
WT samples, suggesting that RBM10-mediated cassette exon
repression acts as an overall gene regulatory mechanism. We
also observed that some RBM10-regulated exons contained a
premature termination codon (PTC), which may cause the tran-
script to be targeted for nonsense-mediated decay (NMD) (Fig-
ure 4E). Genes predicted to contain these poison exons were
significantly more likely to be downregulated compared to other
genes containing RBM10 LoF mutation-induced inclusion
events (p = 1.07e10, Kruskal H test).
FUBP1 LoF Mutation Is Associated with Cassette Exon
Events and Gene Downregulation in LGG
FUBP1 (Far upstream element-binding protein 1) was initially
described to regulate MYC through binding to its far-upstream
element (FUSE), and its overexpression can stimulate MYC
expression (Duncan et al., 1994; He et al., 2000). More recently,
FUBP1 has been described to bind to AT-rich exons andmediate
exon skipping via repression of splicing at the second step
reaction (Li et al., 2013). FUBP1 is located at chromosome 1p,
and its mutation co-occurs in a subset of glioma samples with
1p deletion. Co-deletion of chromosome 1p and 19q in glioma
(Brat et al., 2015), in particular oligodendroglioma, is a common
and early event (Jenkins et al., 2006). LoF mutations of FUBP1 in
the remaining allele would result in complete loss of FUBP1 in
diploid tumor cells. Indeed, we observed significant association
of FUBP1 LoF mutation with the oligodendroglioma histology
subtype, chromosome 1p deletion, and reduced FUBP1 gene
expression in mutant samples compared to WT samples with
1p deletion (Figure 5A).
To investigate the effects of FUBP1 LoFmutations on aberrant
splicing and gene expression, we defined our comparison
groups to be FUBP1 LoF mutation positive (n = 30) versus
WT (n = 31) under IDH1mutation and chromosome 1p/19q dele-(D) Exon inclusion is often concomitant with intron splicing associated with RBM
(E) Exons promoted byRBM10 LoFmutation in LUADmay be predicted to contain
(blue).
See also Figure S3 and Tables S2 and S3.tion-positive background (Figure 5A; Table S4). Differential
splicing analysis identified exon inclusion and exclusion asmajor
alternative splicing events (Figure 5B; Table S3). The FUBP1
RNA expression level and copy number in U87MG, a glioblas-
toma cell line, are similar to our control LGG patient group, offer-
ing an experimental setting to validate our analysis from patient
samples. We transfected U87MG cells with a pool of small
interfering RNAs (siRNAs) against FUBP1, and we performed
RNA sequencing. We first confirmed FUBP1 knockdown at
both protein (Figure 5C) and mRNA (67% depletion) levels.
Differential splicing analysis showed a similar distribution of
aberrant splicing events between transient FUBP1 knockdown
in U87MG cells and in FUBP1 LoF patients (Figure S4A;
Table S3). Though the overlap of significant splicing events
defined by the default q-value threshold of 0.05 was small
among events detected in genes that were expressed in both
patient samples and U87MG cells (11/155 events), splicing junc-
tions upregulated upon FUPB1 loss in patient samples showed
similar, though weaker, upregulation in U87MG (Figure 5D), con-
firming that the observed splicing changes were modulated by
the loss of FUBP1 (p value 4.38e37, binomial test).
Mechanistically, FUBP1 has been shown to preferentially
bind to and inhibit AT-rich exons (Li et al., 2013), and to explore
this relationship we calculated the average AT content profiles
of the cassette exons and the flanking two exons. Compared
to background, we observed significantly higher AT content in
all 3 exons of exon-skipping events (p < 0.00015 in all
three comparisons, Student’s t test) (Figure S4B), an observa-
tion that was recapitulated in FUBP1 siRNA-treated U87MG
cells (p < 0.00019 in all three comparisons, Student’s t test)
(Figure S4C). Although not statistically significant, we also
observed that exons promoted by mutant samples (exon inclu-
sion events) had higher AT content near their 50 ends compared
to exons preferentially included by WT samples, perhaps
contributing to this phenotype. Overall, genes with alternative
splicing events of any type in patient samples (n = 163) were
significantly more likely to be downregulated compared to
background (n = 22,982; p = 4.7e34, Kruskal H test) (Fig-
ure 5E), and, among these spliced genes, we observed that
those with events predicted to result in a transcript degraded
by the NMD pathway were downregulated further (p =
3.0e4, Kruskal H test).
Given the proposed association between FUBP1 and MYC
expression regulation, we also evaluated the potential functional
consequences of FUBP1 LoF on MYC expression and down-
streamMYC signaling. Though we did not see significant reduc-
tion in MYC expression, there was a significant downregulation
of MYC target genes associated with FUBP1 LoF mutations
(Figure S4D; Table S5). We did not observe any MYC target
genes to be alternatively spliced, indicating this downregulation
was independent of FUBP1 functional splicing alterations. Inter-
estingly, we observed that MYC target gene changes were also
correlated in U87MG cells treated with siRNA against FUBP110 LoF mutation in LUAD.
PTCs (red), leading to reduced gene expression compared to those that do not
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(Figure S4E), confirming the independent association between
FUBP1 loss and MYC activity.
Driver Mutations in Splicing Factors Affect Cancer Cell-
Autonomous Pathways and Immune Infiltration
While extensive studies have characterized the splicing aberra-
tions associated with well-known splicing factor genemutations,
the understanding of how these mutations and splicing changes
contribute to selective advantages during tumorigenesis re-
mains unclear. Repeated observations of mutual exclusivity be-
tween different splicing factor driver mutations within the same
disease (Figure 4A) (Papaemmanuil et al., 2013; Haferlach
et al., 2014; Lindsley et al., 2015) suggest either their functional
convergence at the pathway level or that cells cannot tolerate
more than one splicing factor driver mutation. Hence, we con-
ducted systematic pathway analysis in tumor types harboring
driver mutations of the five genes (SF3B1, SRSF2, U2AF1,
RBM10, and FUBP1) with confirmed on-target splicing deregula-
tion (Figure 6A).
First, we performed gene set enrichment analysis (GSEA)
using 50 hallmark gene sets (Subramanian et al., 2005) by
comparing all mutant samples of each gene versus their WT
control group, which was carefully selected to remove con-
founding factors of tumor subtype and other splicing factor
gene mutations (Table S4). We then clustered all comparison
groups and hallmark gene sets using normalized enrichment
scores (NESs) (Figure S5A; Table S5). We observed that com-
parison groups generally clustered by tumor type or similar
cell lineage, rather than by specific splicing factor mutations.
For example, U2AF1 hotspot mutations in LUAD and RBM10
LoF mutations in epithelial tumors BLCA and LUAD group
together, while SF3B1 hotspot mutations in melanomas
SKCM and UVM and SRSF2 hotspot mutations in UVM group
together. Moreover, certain splicing factor mutations in spe-
cific tumor types tended to associate with broad downregula-
tion of cancer hallmark genes, such as SF3B1 hotspot muta-
tions in SKCM and UVM, whereas SF3B1 mutations in BRCA
and U2AF1 in LAML were associated with broad upregulation
of the same hallmarks. This prompted us to further identify
cancer hallmarks commonly regulated by different splicing
factor gene mutations in the same tumor type. Within cohorts,
hallmark gene sets related to immune response, cell cycle
checkpoint and DNA damage response (DDR), and meta-
bolism were associated with splicing factor mutations (Figures
S5B–S5E).
Since hallmark gene sets tend to be broadly defined, we also
conducted enrichment analysis using a set of custom gene sets
containing more specific gene signatures of the hallmark path-
ways uncovered above. In addition, we included spliceosome,
ribosome, proteasome, histone, and NMD pathway genes due
to their functional relevance to the splicing process (Table S6).(C) Western blot of FUBP1 protein following transfection of FUBP1 siRNA pool o
(D) Log2 fold change of splice junctions identified in LGG patient samples (n = 15
(E) Letter-value plot showing that genes with alternative splicing events in LGG
ground (n = 22,982), and genes with splicing changes predicted to result in tran
compared to genes not predicted to be targeted (n = 94). The y axis data range
See also Figure S4 and Tables S3 and S4.We then re-clustered comparison groups and gene sets using
the NESs of these curated gene sets (Figure 6B; Table S7). Strik-
ingly, this analysis revealed that gene sets can be clustered into
two large groups: group 1 (colored green in Figure 6B) contains
mostly cell-autonomous gene signatures of cell cycle, DDR, and
essential cellular machineries; and group 2 (colored purple in
Figure 6B) is composed of immune cell signatures. Among
cell-autonomous gene sets (Figures 6B and 6C), proteasome
genes were upregulated in multiple comparison groups. Ribo-
somal genes were strongly upregulated in SF3B1 hotspot mu-
tants within SKCM and both SF3B1 and SRSF2 mutants in
UVM, three subsets associated with general downregulation of
most gene sets. Cell cycle-related gene sets tended to be
more consistently upregulated in the splicing factor mutant sam-
ples of BLCA and LUAD (Figures 6B and 6C). Among immune cell
signatures, we found that certain subgroups, and in particular
FUBP1 in LGG, were associated with broad upregulation, sug-
gesting that these conditions harbor an increased immune infil-
tration. Alternatively, multiple T cell signatures were consistently
downregulated in SF3B1mutants of UVM as well as splicing fac-
tor mutant subsets of BLCA and LUAD, suggesting that splicing
factor mutations in these tumor types were associated with
fewer T cell infiltrates. To test the hypothesis that the low immune
cell enrichment scores are most likely due to less immune
infiltrates in the tumor microenvironment, we compared lung
adenocarcinoma cell lines with RBM10 LoF mutations to the
WT (Table S4), and we compared the result with that from
LUAD samples (Figure 6D). Three ribosome signatures were
significantly upregulated in both comparisons, and other cell-
autonomous signatures trended very similarly. However, we
observed that most immune cell signatures were only signifi-
cantly downregulated in patient tumor samples and not in cell
lines. Since cancer cell lines are devoid of immune cells, we infer
this is most likely due to reduced immune infiltrates in the tumor
microenvironment.
DISCUSSION
Using matched DNA and RNA sequencing, we have surveyed
33 tumor types for somatic mutations of over 400 splicing factor
genes, and we identified 119 with putative driver mutations. We
observed that the most common mutations are mutually exclu-
sive in each cohort, similar to prior hematological surveys (Pa-
paemmanuil et al., 2013; Haferlach et al., 2014; Landau et al.,
2015), and furthermore induce altered splicing, which is consis-
tent across tumor lineages. Though splicing factor gene muta-
tions were observed in all tumor types, we found that BLCA
and UVM had a significantly higher frequency of putative driver
mutations compared to other cohorts. Together, these results
suggest that splicing deregulation by somatic mutation in cancer
is broader than previously reported.r non-targeting (NT) siRNA pool.
5) in U87MG (blue) compared to LGG patient samples (red).
patient samples (n = 163) are significantly downregulated compared to back-
scripts targeted by the NMD pathway (n = 79) are significantly downregulated
has been terminated at 5, +5 for clarity.
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Curiously, though hotspot mutations in SF3B1 were found in
several cohorts, we observed striking lineage specificity for
certain amino acid changes. Melanomas of both SKCM and
UVM strongly prefer p.R625C/H (21/33 non-silent mutations in
HDs 4–12), while BRCA strongly prefer p.K700E (10/18 non-
silent mutations in HDs 4–12), the samemost frequently mutated
position in hematological malignancies, and p.E902K is only
observed in BLCA. Lineage-specific hotspot mutations are likely
the outcome of the interplay of several contributing factors,
including nucleotide context mutability, gene-specific mutation
rate in the tumor type, lineage-specific interacting partner pro-
teins of a protein complex, and the mutational impact on cancer
genes and pathways to confer survival advantage in a particular
type of cancer. Deconvoluting these complex interactions will be
essential to understand the selective pressures underlying these
mutations.
How splicing factor gene mutations confer selective advan-
tage to tumor cells is an area of active study. Since splicing factor
gene mutations are likely to induce broad transcriptome
changes, it is possible these changes can include splicing of
oncogenes and tumor suppressors. In hematological malig-
nancies, it has been demonstrated that somatic hotspot muta-
tions in SRSF2 leads to mis-splicing and degradation of EZH2
(Kim et al., 2015), a gene known to be recurrently mutated in
those diseases. In another study, SF3B1 mutations in chronic
lymphocytic leukemia (CLL) were shown to lead to mis-splicing
and the production of a truncated form of ATM, another gene
frequently mutated in CLL (Ferreira et al., 2014). In both cases,
these splicing factor mutations have been shown to be mutually
exclusive with mutations of the aberrantly spliced target gene. In
our analysis, we observe previously reported altered splicing of
various cancer genes induced by splicing factor genemutations,
including EZH2 in LAML SRSF2 hotspot mutants and NUMB in
LUAD RBM10 LoF mutants (Bechara et al., 2013). We also find
additional unreported cancer gene alterations. For example,
SF3B1 hotspot mutations in BRCA are associated with mis-
splicing of CDH1, a gene with frequent LoF mutations in invasive
lobular breast cancer (Desmedt et al., 2016). In another example,
both RBM10 LoF and U2AF1 hotspot mutants in LUAD are
associated with TSC2 mis-splicing, a tumor suppressor of the
mTOR pathway (Krymskaya, 2003).
Given the multitude of genes impacted by mis-splicing due
to splicing factor gene mutations, the downstream functional
impact is unlikely to be solely due to the altered splicing of a
single cancer gene. Instead, splicing factor mutations may
cause a transcriptome-wide deregulation of normal splicing
(spliceosome sickness), which induces broad transcriptionalFigure 6. Pathway Enrichment Analysis Using Curated Gene Sets Indic
Lineage Specific
(A) Splicing factor gene mutations and their associated tumor cohorts used in pa
(B) Heatmap of gene set enrichment analyses for all comparison groups genera
distinct subclasses of gene sets are cell-autonomous pathways (green) and imm
(C) Representative cancer hallmark gene sets upregulated in splicing factor mut
(D) Heatmap of NESs comparing patient tumor samples and cell lines, where each
(n = 27 TCGA, n = 3 cell lines) versus RBM10WT (n = 20 TCGA, n = 30 cell lines) o
highlighted with an asterisk.
See also Figure S5 and Tables S4, S5, S6, and S7.programs beneficial to the tumor. Overall, we observed that
different splicing factor genes in the same tumor types are
much more likely to be associated with deregulation of the
same cancer pathways. These results support the idea that
the observed mutual exclusivity of putative driver mutations
within a tumor type might be due to functional redundancy,
though we cannot rule out that co-occurrence of these
mutations may be lethal. Previous functional studies of
splicing factor mutations in SF3B1 and U2AF1 using non-he-
matological tumor cell lines (Zhou et al., 2015; Fei et al.,
2016) indicated that the mutant allele is not essential for cell
survival and does not provide a proliferation advantage
in vitro. Our pathway analysis suggests that, in certain solid
tumors, splicing factor mutations are associated with reduced
immune infiltration and, therefore, may provide selective
advantage to cancer cells through immune evasion. Unlike
SF3B1 and U2AF1, RBM10 has been reported to regulate
splicing of apoptosis and notch pathway genes, and functional
studies of cancer cell lines in vitro and in vivo show that LoF
mutations lead to enhanced colony formation or accelerated
tumor growth (Bechara et al., 2013; Herna´ndez et al., 2016;
Zhao et al., 2017). Our analysis comparing RBM10 LoF muta-
tions in tumor samples and in cancer cell lines complements
the existing studies, and it proposes that loss of this splicing
factor has an immunosuppressive role in addition to its cell-
autonomous growth-promoting role.
Cancer-specific splicing changes are increasingly recog-
nized to contribute to tumorigenesis via various mechanisms.
Multiple oncogenes and tumor suppressors have been re-
ported to express cancer-specific or treatment-resistant
splice variants (Zhang and Manley, 2013). In another survey
of the extent of somatic single-nucleotide variants (SNVs)
altering splicing, a large number of SNVs are found to cause
intron retention in tumor suppressors and loss of function
through NMD or truncated proteins (Jung et al., 2015). Alter-
natively, splicing factors can act as proto-oncogene or tumor
suppressors when their expression is altered in cancer
(Anczuko´w et al., 2015; Jiang et al., 2016). The spectrum of
splicing factor gene mutations that occur in multiple tumor
types highlights somatic mutation as an important mechanism
of splicing deregulation in cancer, the scope of which we are
just starting to uncover. Collectively, these observations
suggest deregulated RNA splicing as a hallmark of cancer.
More functional studies are clearly needed to understand
the impact of RNA-splicing changes and splicing factor
mutations and, most importantly, their contribution to cancer
development.ates that Cancer Pathways Altered by Splicing Factor Mutations Are
thway analyses.
ted using normalized enrichment scores (NESs) of 46 curated gene sets. Two
une-related signatures (purple).
ant samples.
column represents the differential pathwaymodulation ofRBM10 LoFmutants
f 46 curated gene sets. Significantly modulated gene sets (q value% 0.05) are
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
U87MG (male, glioblastoma) cells were obtained from ATCC (ATCC HTB-14) and cultured in ATCC-formulated Eagle’s Minimum
Essential Medium (30-2003) supplemented with 10% fetal bovine serum (FBS) at 37C with 5% CO2 and 95% humidity. Cell authen-
tication was conducted at IDEXX BioResearch using STR DNA profiling and found to be 100%matching markers listed in the ATCC
database for U87MG cells, with no species contamination.Cell Reports 23, 282–296.e1–e4, April 3, 2018 e1
METHODS DETAILS
Compilation of splicing factor genes
Wecollected 1512 spliceosome and splicing related genes from three sources: 1) 244 spliceosome proteins reported in (Hegele et al.,
2012) from a comprehensive yeast two hybrid study using spliceosome components as bait, 2) 254 splicing factors and splicing
related proteins annotated in (Barbosa-Morais et al., 2006) Table S6, and 3) 1100 genes from SpliceosomeDB (Cvitkovic and Jurica,
2013). The latter two are curated component lists derived from other publications. All gene identifiers are standardized into HUGO
symbol and EntrezID. We prioritized the final list of 404 splicing factor genes (Table S1) by including all genes from sources 1) and 2),
and genes from 3) if they are annotated in as ‘‘complex-SpliceosomeDB’’ or ‘‘class/family-SpliceosomeDB’’ excluding ‘‘commonMS
contaminants,’’ or if they belong to the same protein families from any genes above. The reason we used this conservative approach
to prioritize genes in 3) is that some genes, though identified by mass spectrometry experiments in certain spliceosomes, have
undefined functions and orthologs across species and hence could simply be contaminants in sample preparations found associated
with human spliceosomes.
Detection of somatic mutation and identification of splicing factor genes with driver mutations
Somatic mutation data was provided by TCGA MC3 working group (see Key Resources Table). We considered a sample ‘‘splicing
factorWT’’ (and therefore appropriate for use in differential splicing or gene expression contexts) if therewere no non-silent mutations
in any known splicing factor genes.
MutSigCV analytical results were downloaded from Broad TCGA Firehose dashboard on September 2016 (https://confluence.
broadinstitute.org/display/GDAC/Dashboard-Analyses). MutSig2CV3.1 results were used when available. A q-value cut-off of
0.1 was used to define significantly mutated genes in each cohort. We excluded PAAD cohorts from this analysis as samples in
this cohort typically had extremely low non-silent mutation counts.
For the ratiometric method, we defined mutational hotspots (HS) as missense or in-frame deletion mutations at the same
protein position > = 3 pan-TCGA. Loss of function (LoF) mutations were defined as any of the following mutation classifications
(Frame_Shift_Del, Frame_Shift_Ins, Nonsense, Splice_Site). We then calculated %HS or %LoF as the total number of hotspot or
LoF mutation-positive samples divided by total number of non-silent mutations per gene per cohort. The ‘‘pancan’’ cohort encom-
passes all samples in TCGA. We used empirical cut-offs to define genes as HS or LoF type, specifically:
If %HS > = 30% and %LoF % 20% and HS counts > = 3, a gene is called ‘‘hotspot’’ in that cohort, and if %LoF > = 30% and
%HS% 20% and LoF mutation counts > = 10, a gene is called ‘‘LoF’’ type in that cohort.
An extended ratiometric method published by Tokheim et al. (Tokheim et al., 2016) called ‘‘20/20+’’ was used as an additional
evaluator of putative driver splicing factors. This method uses a random forest-based method trained on known cancer driver genes
to identify cohort-level cutoffs appropriate for this identification. For each cohort (as well as the ‘‘pancan’’ cohort), the pre-trained
random forest classifier provided by Tokheim et al. was used to assign Benjamini-Hochberg corrected q-values to each gene
with q < 0.1 used as a cutoff for significance. These results are given in Table S1. All genes were plotted using oncogene score
and tumor suppressor gene score provided by 20/20+, with significant genes labeled and colored based on the larger of the two
scores (i.e., red genes have higher oncogene score than tumor suppressor score, whereas blue genes the opposite) (Figure S1C).
Detection of additional samples with hotspot mutations of SF3B1, U2AF1, and SRSF2
Following read alignment by STAR allowing multimapping reads of RNaseq files, samples were interrogated for functional hotspot
mutations in known driver splicing genes SF3B1, U2AF1, and SRSF2. For SF3B1, amino acids p.E622, p.Y623, p.R625, p.N626,
p.H662, p.T663, p.K666, p.K700, p.V701, p.I704, p.G740, p.K741, p.G742, and p.D781 (Darman et al., 2015, Obeng et al., 2016)
were used. For U2AF1, amino acids p.S34, p.R156, and p.Q157 were used (Papaemmanuil et al., 2013; Lindsley et al., 2015). For
SRSF2, mutations and deletions in/near amino acid p.P95 were used (Zhang et al., 2015, Kim et al., 2015). Samtools (Li et al.,
2009) mpileup was used for genotyping, and only uniquely mapped reads were allowed. A minimum total read coverage
of 10 was imposed for the codon encoding amino acid changes in these genes as well as a minimum read coverage of 4 supporting
the change. Mutations with allele frequency < 5% were ignored. We also performed visual inspection using Integrative Genomic
Viewer (IGV, Robinson et al., 2011) and indel mis-calls were manually corrected.
Prioritization of genes for differential splicing and pathway analysis
We prioritized two groups of genes for in-depth differential splicing and pathway analysis. Group 1 includes SF3B1, SRSF2 and
U2AF1. Driver mutations of these genes are well reported with high frequency in hematological tumors and their associated splicing
changes are well studied. The goal is to understand how similar or potentially different their somatic mutations and their associated
splicing changes are pan-cancer. Group 2 includes other genes with exceptional high mutation frequency and compelling hotspot or
LoF mutation patterns. RBM10 and FUBP1 are the top 2 splicing factor genes by frequency of mutation, both with a strong LoF
mutation pattern.e2 Cell Reports 23, 282–296.e1–e4, April 3, 2018
Principal component analysis of mutant and wild-type splicing factor samples
Junction counts for all TCGA samples were obtained from Omicsoft OncoLand 2016 Q2 release and converted to PSI. SF3B1
mutation information was obtained from TCGA pan-cancer MC3 data and validated using RNA-Seq data. Alternative 30 splice sites
promoted by SF3B1mutant (HD4-8) activity were obtained from Darman et al., 2015 (Darman et al., 2015). Alternative 30 splice sites
and exon inclusion events promoted by SF3B1 p.E902K versus splicing factor WT samples in BLCA (Table S3) are used to stratify
patient samples in Figure S2B.
Letter-value plot
Letter-value plots (Hofmann et al., 2017) are an extension of the standard boxplot for large-scale data. The seaborn python package
(see Key Resources Table) was used with the depth parameter ‘‘proportion,’’ where 0.007 is assumed the fraction of samples which
are outliers in a given cohort. Letter-value boxes (percentiles of the data, which start at 50% and decrease by half each iteration) are
drawn until this fraction is reached. Boxes are colored based on the density of points within, where darker colors indicate higher
density.
Pathway analysis
Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) was performed using cancer hallmarks and the curated gene sets.
Default parameters were chosen except theminimum gene set size was set to 5. The gene expression for each cohort was defined as
the mean Log2 transcripts per million (TPM) (i.e., log2(1+tpm)). The R package limma (Ritchie et al., 2015) was used for differential
gene expression analysis after filtering out low-expressed genes (maximum TPM < 3), and gene lists ranked by moderated t-statistic
values were used as input for GSEA.
Clustering analysis of normalized enrichment score (NES) was done using the R (R Development Core Team, 2011) package using
heatmap software from (https://raw.githubusercontent.com/obigriffith/biostar-tutorials/master/Heatmaps/heatmap.3.R)
Curation of gene sets (Table S6)
The following custom gene sets for enrichment analysis:
1. Cell cycle gene sets were obtained fromQIAGEN human cell cycle PCR array Cat. No. PAHS-020Z (http://www.sabiosciences.
com/rt_pcr_product/HTML/PAHS-020Z.html).
2. DNA damage response/repair (DDR) gene sets were shared with us by TCGA PanCanAtlas DDR analysis working group.
3. Immune gene sets were obtained from the publication by Newman et al., 2015.
4. Proteasome gene set was obtained from HUGO Gene Nomenclature Committee (HGNC) under gene family proteasome
(http://www.genenames.org/cgi-bin/genefamilies/set/690) and Kyoto Encyclopedia of Genes and Genomes (KEGG) protea-
some (http://www.genome.jp/kegg/pathway/hsa/hsa03050.html).
5. Ribosome gene sets were obtained from Ribosomal Protein Gene Database (RPG) (http://ribosome.med.miyazaki-u.ac.jp/)
and KEGG ribosome (http://www.genome.jp/kegg/pathway/hsa/hsa03010.html).
6. Spliceosome is in Table S1.
7. Nonsense mediated decay (NMD) gene set was curated based on two publications (Nicholson et al., 2010; Kervestin and
Jacobson, 2012).
8. Histone gene list were obtained fromHUGOGene Nomenclature Committee Histone gene family (http://www.genenames.org/
cgi-bin/genefamilies/set/864)
9. Antigen presentation gene set was from Reactome: (http://software.broadinstitute.org/gsea/msigdb/cards/REACTOME_
ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC.html). It captures the
key elements, while excluding things that are redundant from other customer gene lists (e.g., proteasome).
FUBP1 Knockdown in U87MG and RNA Sequencing
U87MG cells were obtained from ATCC (ATCC HTB-14) and cultured in ATCC-formulated Eagle’s Minimum Essential Medium
(30-2003) supplementedwith 10%FBS.ON-TARGETplus Non-targeting siRNAPool (D-001810-10-05) andON-TARGETplus Human
FUBP1 siRNA SMARTpool (L-011548-00-0005) were obtained from Dharmacon. To knock down FUBP1, 250,000 U87MG cells were
seeded per well in six-well plates. On the second day, either the non-targeting siRNA pool or the human FUBP1 siRNA pool was
transfected into U87MG cells in quadruplicates using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific),
according to the manufacturer’s manual. The final concentration of the siRNA pool was 50 nM in each well; 3 days after transfection,
medium was refreshed. At 5 days post-transfection, one well of either non-targeting siRNA pool- or FUBP1 siRNA pool-transfected
cells was harvested in radio immunoprecipitation assay (RIPA) buffer supplemented with proteasome complete protease inhibitor
cocktail and PhosStop phosphatase inhibitor cocktail (Roche Life Science) for western blot analysis to examine the knockdown
efficiency. Specially, equal amounts of protein lysates were loaded onto 4%–12% NuPAGE Bis-Tris gels (Thermo Fisher Scientific)
before being transferred ontoNitrocellulosemembrane using the iBlot2 dry blotting system (Thermo Fisher Scientific). Themembrane
was blocked with LI-COR buffer and then incubated with rabbit polyclonal anti-FUBP1 antibody (Abcam ab181111) and monoclonal
anti-GAPDH antibody (Sigma G8795) overnight in a cold room. On the second day, the membrane was washed three times withCell Reports 23, 282–296.e1–e4, April 3, 2018 e3
tris-buffered saline Tween 20 (TBST) and incubated with LI-COR IRdye secondary antibodies before TBSTwash, and it was scanned
and quantified using LI-COR Odyssey imaging system. For RNA extraction, the remaining three wells for each transfection were
harvested with RNeasy lysis buffer, and total RNAs were extracted using RNeasy column kit (QIAGEN), following the manufacturer’s
protocol. Extracted total RNAs were analyzed on Agilent Tapestation to ensure RNA quality before being submitted to Beijing
Genomic Institute (BGI) for polyA+ RNA sequencing (RNA-seq) library preparation and sequenced on Illumina Hiseq 4000.
Differential Splicing Analysis and NMD Prediction
Differential splicing analysis was performed similar to previously describedmethodology (Darman et al., 2015). In brief, raw sequence
reads were extracted from BAM files made available through TCGA, then aligned using STAR using two-pass alignment (Dobin et al.,
2013) to human reference genome GRCh37/hg19. Junction PSI was calculated for all sets of junctions that shared a single common
ss as the number of raw reads supporting that junction divided by the total number of reads in all junctions sharing that ss. We
accounted for intron retention in PSI calculations by counting reads that completely overlapped a 6-nt window around the ss (3 nt
within the intron and 3 nt within the exon) as intron retention reads. Read count for each junction was pooled in the FUBP1 siRNA
versus non-targeting siRNA cell line comparison to increase statistical power. Each PSI measurement was converted to log odds
via the formula log(p/(1-p)) before being compared using either a moderated t test (Ritchie et al., 2015) (patient samples) or binomial
test (cell lines) between cohorts. False discovery rate (FDR)-corrected q-values < 0.05 for junctions promoted by the case or mutant
cohort (alternative junction) were considered significant. To be reported as a splicing event, at least one junction promoted by the
control, orWT case (canonical junction[s]), that shared an ss with the alternative junction was also required to have an FDR-corrected
q-value < 0.2, and these are reported in Table S3. For intron retention events, both 50 and 30 exon-intron boundaries were required to
be significant, and a minimummedian threshold for mean intron read coverage over all samples in that cohort was set at 0.1 in order
to reduce false positives. NMD prediction was performed for each splicing event by first identifying all RefSeq transcripts that con-
tained an intron that shares an ss with the mutation-promoting junction and then determining the novel peptide sequence that
resulted from altering that transcript to contain the splicing event (Darman et al., 2015). Events were predicted to be NMD-targeted
if all affected transcripts contained a stop codon > 50 nt from the final exon-exon junction.
QUANTIFICATION AND STATISTICAL ANALYSIS
The details of each statistical test are contained within the Results, including the total number of samples (n) in each case and control
condition, as well as the test used. Unless otherwise specified, p values less than 0.05 were considered significant. Multiple testing
correction was performed where applicable using the Benjamini-Hochberg FDR correction, and q-values less than 0.05 were
considered significant unless otherwise specified.
Differential Gene Expression
Gene differential expression was performed using the limma package following quantification using Kallisto (Bray et al., 2016).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA sequencing data fromU87MGcells reported in this paper is GEO:GSE100530. All other data used
are available from the Genomic Data Commons (https://portal.gdc.cancer.gov/).e4 Cell Reports 23, 282–296.e1–e4, April 3, 2018
